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Abstract 
Objectives: Research has found menopausal transition, the perimenopause, to be associated 
with an increased risk of depressive symptoms. Many studies focused on treatment options to 
improve psychological well-being of perimenopausal women. However, to date it is unknown 
which treatment, including hormone replacement therapy (HRT), antidepressants (AD) or a 
combination, is most effective. In this thesis we want to investigate and provide an answer as 
to which treatment is most effective in reducing depressive symptoms in perimenopausal 
women. 
Methods: Computerised literature searches were performed with “major depression” and 
“menopause” as main search terms. Studies were considered if they included a measure of 
depressive symptoms and menopausal status was examined according STRAW-criteria. 
Comprehensive Meta-Analysis (CMA) was used for the analysis. Effect sizes were analyzed 
using the random effects model, in which the error term is composed of variation originating 
from both within-study variability and between-study differences. 
Results: Six studies were included in the meta-analysis. No significant difference was found 
between the effects of HRT versus placebo on reducing depressive symptoms. AD compared 
with placebo showed that AD is more effective than placebo (effect size = -1.868, z = -4.937, 
p < 0.001). AD compared with HRT had an effect size of -1.460, p = 0.033.  
Conclusion: The results of this meta-analysis should be interpreted with great caution, 
because of the small number of included studies. AD therapy was found to be more 
efficacious in treating depressive symptoms of perimenopausal women than placebo and 
HRT. The efficacy of HRT in reducing depressive symptoms in perimenopausal women 
cannot be established. However, further research is recommended.  
 
 
 
 
 
 
 
1. Introduction  
The menopausal transition is associated with an increased risk of depressive symptoms for 
women, independent of demographic, behavioral, psychosocial and health factors 
(Bromberger et al., 2007). Many studies focused on treatment options to improve 
psychological well-being of perimenopausal women. However, to date it is unknown which 
treatment, including Estrogen-Replacement Therapy (ERT), Hormone-Replacement Therapy 
(HRT), Antidepressants (AD) or a combination, is most effective in the treatment of 
perimenopausal women.  
1.1. Characteristics of Depression 
Depression is common and associated with functional impairment. According to the 
Central Statistics Office (2013) in 2012 one out of ten adults in the Netherlands felt 
depressed. The twelve-month prevalence of adults with a depressed mood or a depression in 
the Netherlands is 7.9% for men and 13.1% for women (Verweij & Houben-Van Herten, 
2013). In the Diagnostic and Statistical Manual of mental disorders (DSM-5; American 
Psychiatric Association, 2014), the criteria for a major depressive disorder or a depressive 
episode are a depressed mood or a loss of interest/pleasure in daily activities for more than 
two weeks. At least 5 of the 9 specific symptoms have to be present nearly every day:  
depressed mood or irritability, decreased interest or pleasure in most activities, significant 
weight change, change in sleep, change in activity, fatigue or loss of energy, guilt or 
worthlessness, concentration problems and suicidality (DSM-5, 2014).   
1.2. Menopausal transition  
The STages of Reproductive Aging Workshop (STRAW) is the standard for 
characterizing reproductive aging through menopause. The staging recommendations are 
restricted to menstrual cycle bleeding and Follicle-Stimulating Hormone (FSH) levels. 
STRAW divides the adult female life into three phases: premenopause (reproductive years), 
perimenopause and postmenopause, see Figure 1 (Harlow et al., 2012).  The early menopausal 
transition starts at stage -2 and is marked by an increased variability in menstrual cycle length 
and a difference of 7 days or more in the length of consecutive cycles. Most women enter this 
stage in their 40’s, with a mean age of 47.5 years (Soares, Poitras & Prouty, 2003). The late 
menopausal transition starts at stage -1 and is defined as amenorrhea for 60 days or longer. 
This stage is characterized by an increased variability in cycle length, extreme fluctuations in 
hormonal levels and FSH levels greater than 25 IU/L. The end of the 12-month period of 
amenorrhea starts at stage +1a and is defined as the postmenopause (Harlow et al., 2012).
 
 
Figure 1. STRAW+10 staging system for reproductive aging in women (Harlow et al., 2012) 
The transition from premenopause to perimenopause, the menopausal transition, is for 
some women a period of increased vulnerability for a depression or depressive symptoms 
(Bromberger et al., 2007; Schmidt, 2005). It has been found that depressive symptoms or the 
development of a first episode of depression significantly increase during menopausal 
transition, even after controlling for variables such as a history of depression or important life 
events (Cohen, Soares, Vitonis, Otto & Harlow, 2006; Freeman et al., 2004). Many studies 
concluded that women who entered the perimenopause or early postmenopause were 2 to 4 
times more likely to experience a major depression or a major depressive episode compared to 
premenopausal women (Bromberger et al., 2011; Freeman, 2010; Cohen et al., 2006).  
 
 
 
1.3.  Gender differences, hormonal fluctuations and attitude toward menopause 
Depression is more common among women than men. The World Mental Health 
Survey initiative reports for the Netherlands a 2:1 rate of depression for women compared to 
men, during a 12-month major depressive episode (Odds Ratio (OR)=2.3) (Bromet et al., 
2011).  An explanations for this gender difference can be found in the tendency to seek help, 
role differences, biological differences, exposure to stressful life events and coping factors 
(Hammen & Watkins, 2008). In this thesis, the biological differences between men and 
women are a topic of interest.  
It is known that the brain responds to fluctuating hormone levels and will modify its 
function. In female brains a cyclic hormonal fluctuation occurs, because of the menstrual 
cycle. This requires a flexible and responsive mechanism to compensate for changes in 
neuroendocrine input (Deecher, Andree, Sloan & Schechter, 2008). During the menopausal 
transition these cycles become irregular and result in changeable hormone levels (Deecher et 
al., 2008; Harlow et al., 2012). During this period, hormone levels fluctuate. Estrogen levels 
increase during early perimenopause, before dropping and FSH levels will increase and 
stabilize at the postmenopausal state (Gibbs, Lee & Kulkarni, 2012). The female brain has to 
adapt to these changes in menstrual cycle and fluctuating hormone levels. According to Gibbs 
and colleagues (2012), the fluctuations in reproductive hormones could lead to a depression in 
vulnerable women, while Deecher and colleagues (2008) think that the inability to rapidly 
respond to these hormonal changes in the brain can lead to mood disorders.  
Another explanation could be that neuroendocrine changes in the Hypothalamic-
Pituitary-Gonadal (HPG) axis lead to lower levels of the neurotransmitter serotonin (5-
Hydroxytriptamine receptors (5-HT)). The hormonal fluctuations during menopausal 
transition effects the HPG axis, which influences the function of 5-HT receptors. Lower levels 
of serotonin have been associated with depressive symptoms or a depression in combination 
with stressful life events (Deecher et al., 2008). This could be an alternate explanation for the 
increased risk on depressive symptoms or a depression in the perimenopause state (Deecher et 
al., 2008). 
Also, the relation between attitudes towards the menopause and women’s symptom 
experience has been investigated. It has been found that women with more negative attitudes 
prior to menopause experience higher frequencies of hot flushes during menopause (Ayers, 
Forshaw & Hunter, 2010). In another study with healthy women it was found that a negative 
attitude toward aging was associated with later higher symptom intensity (Nosek et al., 2010). 
For these reasons, it is plausible that women experience and express more often depressive 
symptoms or a depression than men, especially during this period of their lives.  
1.4. Treatment for women in perimenopause 
There are many treatment possibilities for perimenopausal women with depressive 
symptoms or a depression, including for instance Estrogen-Replacement Therapy (ERT), 
Hormonal-Replacement Therapy (HRT) and antidepressants. The goal of most treatments is 
to improve psychological well-being. 
ERT and HRT are both hormonal-replacement therapies, which only differ in the 
addition of the hormone progestin to HRT. The combination of estrogen with progestin is 
needed for women with an uterus, to prevent irregular bleeding and to lower the risk of 
endometrial cancer (Studd, 2011). The route of administration in most studies is by 
transdermal skin patches (Soares, 2003). ERT and HRT lead to symptom relief of vasomotor 
symptoms, such as hot flushes and night sweats. Where a decrease in estrogens led to vaginal 
dryness and a loss of libido, an increase of estrogens can alleviate this symptoms (Studd, 
2011). All treatments are associated with risk factors; ERT and HRT are no exception to this 
rule. There is an increased risk of breast cancer and cardiovascular events. To avoid increased 
risk, the use of this treatments should be limited to three to five years (Gordon & Girdler, 
2014; Parry, 2010).  
Widely used antidepressant treatments for women in perimenopause are Selective 
Serotonin Reuptake Inhibitors (SSRI) or Selective Serotonin and Noradrenalin Reuptake 
Inhibitors (SNRI) as paroxetine, fluoxetine, desvenlafaxine and escitalopram. SSRI’s are 
believed to increase the level of serotonin by inhibiting the reuptake of this neurotransmitter. 
SNRI’s work the same way, but act upon the neurotransmitters serotonin and noradrenalin. 
SSRI’s and SNRI’s improve mood and vasomotor symptoms (Soares et al., 2003). Most 
reported side effects of antidepressants are jitteriness, headache and nausea, but usually these 
side-effects will abate in the first weeks of the treatment. It can take six to eight weeks to 
achieve response and effectiveness (Santoro, Epperson, Mathews, 2015).  
Different studies report different results for the treatments ERT, HRT and 
antidepressants for depression or depressive symptoms in perimenopausal women. In a study 
of Kornstein, Clayton, Bao and Guico-Pabia (2015) the antidepressant desvenlafaxine (SNRI) 
showed a significant effect in both perimenopausal and postmenopausal women with a major 
depressive disorder, with a therapeutic dose of 50 mg/day. In this study depressive symptoms 
reduced significantly in perimenopausal women treated with desvenlafaxine compared to 
untreated perimenopausal women (Kornstein et al., 2015). In a previous study the 
effectiveness of the antidepressant escitalopram (SSRI) in perimenopausal women has been 
investigated. Remission was experienced by 12 out of 13 women who completed the entire 
trial. This study concluded that escitalopram is an effective and well tolerated treatment of 
depression in perimenopausal women (Freeman et al., 2006). Gartrell and colleagues (2001) 
reported that symptom relief was experienced by 57 percent of peri- and postmenopausal 
women when they were treated with antidepressants (SSRI’s). For comparison, with HRT 
only 23 percent of the peri- and postmenopausal women experienced symptom relief (Gartrell 
et al., 2001).   
According to Rubinow and colleagues (2015) there is little evidence to support the 
antidepressant efficacy of estradiol in perimenopausal women (Rubinow, Lanier Johnson, 
Schmidt, Girdler & Gaynes, 2015), and Parry (2010) concluded that estrogen treatment alone 
has not been shown as an efficacious monotherapy in major depressive disorders. The 
addition of estrogen to an antidepressant therapy with SSRI has been recommended to 
enhance the efficacy of this treatment (Parry, 2010). This is supported by another study, 
which reports that if you want to improve the efficacy of estrogens an addition of 
antidepressant is recommended (Studd, 2011).   
 1.5. Research questions 
Many perimenopausal women experience depressive symptoms and may be treated 
with hormone replacement and/or antidepressant therapies. However, to date it is unknown 
what kind of treatment, including ERT, HRT or AD, is most effective for women in 
perimenopause who are experiencing depressive symptoms. In this thesis we want to 
investigate and provide an answer as to which treatment is most effective in reducing 
depressive symptoms in perimenopausal women, by performing a meta-analysis. It could be 
expected that both hormone-replacement therapies, such as ERT/HRT and antidepressant 
therapies are effective treatments. However, as the relation between circulating hormones and 
occurring menopausal symptoms during perimenopause is not very clear and controversial, 
we expect antidepressants as a monotherapy or a combination of hormone replacement 
therapies and antidepressants to be more effective in the treatment of depressive symptoms in 
perimenopause than hormone replacement therapy alone. 
2. Methods 
 
2.1 Design 
The design of this study is a meta-analysis.  
 
2.2. Search of eligible studies for meta-analysis 
 
In 2013 a psychiatrist of PsyQ Den Haag started with searching for relevant articles 
for the meta-analysis. Relevant articles were identified by the following search terms: 
Major depression, major depressive disorder in combination with the search terms 
menopause, perimenopause, climacteric and female hormones, gonadal steroids, sex 
hormones. Searches for articles on perimenopausal, menopausal, climacteric and involutional 
depression were also performed. The restrictions for these searches were humans, females and 
English language articles. This search led to 3,245 articles.  
At first sight all articles were screened on title and abstract, which led to an elimination of 
2,375 articles. Studies were considered if they included a measure of depressive symptoms 
and menopausal status was mentioned. With 870 articles left, the articles were further 
screened on in- and exclusion criteria.  
 
The inclusion criteria were 1) a clear definition of menopause according STRAW, 2) 
subjects who were perimenopausal, 3) the use of a validated depressive scale, and 4) the 
presence of a diagnosis of depression according to a clinical interview.  Studies were excluded 
if 1) it did not contain a treatment for perimenopausal women, 2) results were mixed for pre, 
peri- and postmenopausal women, 3) results of used depressive scales were not mentioned, 
because it was not significant or another reason, and 4) women were in a menopause clinic. 
This resulted in 105 relevant articles for the meta-analysis, which were further screened on 
data and usability. Many studies were not eligible for this meta-analysis, because of in- and 
exclusion criteria.  Approximately 25 authors have been contacted by email and were 
requested for more detailed study results or results that were not mentioned because these 
were not significant. Only three authors responded. Studies of authors who did not respond 
were excluded. A total of 6 eligible articles were included in this meta-analysis into the most 
effective treatment for perimenopausal women. See Figure 2 for the flow chart of eligible 
studies. 
 
2.3. Statistical Analysis 
 
The statistical program Comprehensive Meta-Analysis version 2.0 (CMA) was used 
for the analysis (Borenstein, Hedges & Rothstein, 2007). Before entering data in CMA, the 
results from the studies were computed into effect size Cohen’s d. The effect size Cohen’s d 
has been calculated with an effect size calculator (http://www.uccs.edu/~lbecker/). Effect 
sizes were analyzed using the random effects model, in which the error term is composed of 
variation originating from both within-study variability and between-study differences 
(Borenstein, Hedges & Rothstein, 2007). The core analysis included the point estimate of the 
standard difference in the means, standard error, variance, 95% confidence interval (CI), Z-
score and statistical significance. Heterogeneity was assessed by using the Q-statistic, its 
associated p-value and the I-squared. Significant heterogeneity indicates that differences 
across effect sizes are likely due to sources other than sampling error, such as different study 
characteristics. For all tests, significance was defined at p < 0.05.   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Search of eligible studies/flow-chart 
 
 
3245 Potentially relevant abstracts 
2375 Abstracts excluded (not relevant)    
  
 870 Potentially relevant articles 
765 Articles are excluded from  
meta-analysis: 
- No presence of a depressive disorder 
- No validated depressive scale 
- No clear definition of menopause 
105 Articles are considered for           
Meta-analysis 
99 Articles are excluded from  
meta-analysis: 
- If it did not contain a treatment for 
perimenopausal women 
- Results were mixed for pre-, peri- and 
postmenopausal women 
- Results of used depressive scale were 
not mentioned 
- If women were in a menopause clinic 
6 Articles included in meta-analysis for 
treatment of depression or depressive 
symptoms of women in perimenopause.  
2 Antidepressants (AD) 
 1 Hormone Replacement (HRT) 
 2 HRT + placebo 
 1 ERT + AD 
  
3. Results 
3.1. Characteristics of the studies 
A total of six studies met all inclusion criteria and were used for the meta-analysis.  
Table 1 displays the characteristics of these studies such as treatment, number of women, 
measurement instruments and the effect size. Table 2 displays the statistics for each study.  
Table 1. Characteristics of studies 
 
Study, year  Treatment   Perimenopausal Depression Duration 
  
       Women (N) Measurea  weeksb  
 
Björn et al., (2003)  17β-estradiol, 2 or 3 mg/d and addition 38  CD-scale  10  
   of MPAC on day 17-28.       
 
Cassano et al., (2005) Fluoxetine, 20 mg/d (fixed dose)  28  HAM-D17 8 
   
Ladd et al., (2005)  Venlafaxine, 75-225 mg/d  16  HAM-D17 8 
  
Rasgon et al., (2002)  17β-estradiol, 0.3 mg/d or  16  HAM-D28 8  
   as an adjunct to fluoxetine 30,0 ± 4,8 mg   
     
Schmidt et al., (2005) 17β-estradiol, 0.05 mg/d,   34  CES-D  4  
additional 1 wk of combined  
estradiol and MPA (10 mg/d)       
  
Soares et al., (2001)  100μg 17β-estradiol or placebo   50  MADRS  12 
   skin patches. 
Note.   
a. CD-scale: CyclityDiagnoser, HAM-D: Hamilton Rating Scale for Depression, CES-D: Center for Epidemiologic Studies 
    Depression, MADRS: Montgomery-Asberg Depression Scale.  
b. Duration in weeks: The shortest or most effective period in weeks  
c. MPA: Medroxyprogesterone acetate 
 
 
The six studies included four studies on ERT/HRT; two of these studies used a control group 
(placebo). In two studies AD were examined in the treatment of depression in perimenopausal 
women. As only one study compared the effects of ERT and AD combined, it was not 
possible to examine the efficacy of combined treatment.  
 
 
 
 
Table 2. Statistics for each study  
Study, year  Treatment Effect sizea 95% CI     z-value p-value 
       Lower limit Upper limit 
 
Björn et al., (2003)  HRT  1.317  0.739  1.895  4.467 0.000 
Cassano et al., (2005) AD  -2.432  -3.122  -1.741  -6.899 0.000 
Ladd et al., (2005)  AD  -2.057  -2.972  -1.141  -4.401 0.000 
Rasgon et al., (2002)  ERT  -1.855  -2.903  -0.807  -3.468 0.001 
Schmidt et al., (2005) HRT   -1.697  -2.505  -0.889  -4.116 0.000 
   Placebo  -2.246  -3.081  -1.412  -5.277 0.000 
Soares et al., (2001)  HRT  -2.123  -2.816   -1.429  -6.002 0.000 
   Placebo  -0.876  -1.457  -0.296  -2.959 0.003 
Note. 
a. Effect size: Standardized difference in means 
 
3.2. Testing the research questions  
3.2.1. What is more effective: AD or Placebo?   
The mean effect size of the two studies on AD was -2.259 (95% CI, -3.309 to -1,210, p < 
0.001). The mean effect size of the placebo group (based on two studies) was -1.502, p 
<0.001. Four studies comparing AD with placebo showed that AD is more effective than 
placebo (effect size = -1.868, z = -4.937, p < 0.001. Heterogeneity was significant, Q (3) = 
14.233 (p = 0.003) and I² = 78.921, indicating that 78.92% of the observed variance reflects 
real differences in effect sizes.  
3.2.2. What is more effective: HRT or Placebo?   
The mean effect size of the HRT group was -1.068 (95% CI, -2.738 to 0.601, p = 0.210). The 
effect size of the placebo group was -1.550 (95% CI, -3.898 to 0.798, p = 0.196). The random 
effects analysis showed an effect size of -1.230, z= -1.772, p = 0.076.  Thus, no significant 
difference was found between the effects of HRT versus placebo on reducing depressive 
symptoms. Heterogeneity was significant, Q (5) = 85.431, p < 0.001 and I² = 94.147. 
 
 
Table 3. Random effects analysis 
Treatment Number of studies Effect size Lower limit Upper limit z-value p-value 
AD  2   -2.247  -4.576  0.082  -1.891 0.059 
HRT  4   -1.068  -2.713  0.577  -1.272 0.203 
Overall  6   -1.868  -2.804  -0.117  -2.130 0.033 
 
3.2.3. Which treatment is more effective: AD or HRT? 
The AD group compared with HRT group had an effect size of -1.460, p = 0.033, see Table 3. 
AD was found to be more efficacious in treating depression than HRT. Heterogeneity was 
significant, Q (5) = 98.065, p < 0.001 and I² = 94.901. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. Discussion 
4.1. Answers to the research questions 
The aim of this meta-analysis was to understand more about the treatment of 
depressive symptoms in the perimenopause, a period of hormonal imbalances with an 
increased risk of developing depressive symptoms. We were interested in the most effective 
treatment for women in perimenopause who are experiencing depressive symptoms.  
AD therapy was found to be more efficacious in treating depressive symptoms of 
perimenopausal women than placebo and HRT. This meta-analysis provides supportive 
evidence for the efficacy of the antidepressants fluoxetine (SSRI) and venlafaxine (SNRI) in 
improving psychological well-being of perimenopausal women (Cassano et al., (2005); Ladd 
et al., 2005). Other studies support these findings. In the study of Kornstein, Clayton, Bao and 
Guico-Pabia (2015) depressive symptoms reduced significantly in perimenopausal women 
treated with desvenlafaxine. Other antidepressants, for example, escitalopram (SSRI) has been 
concluded efficacious in the treatment of depression in perimenopausal women (Freeman et 
al.,2006).   
In this meta-analysis no significant differences were found between HRT and placebo. 
Thus, the efficacy of HRT in reducing depressive symptoms in perimenopausal women 
cannot be established. This is supported by the study of Gartrell and colleagues (2001).  They 
reported that symptom relief was experienced by 57 percent of peri- and postmenopausal 
women when they were treated with antidepressants (SSRI’s). For comparison, with HRT 
only 23 percent of the peri- and postmenopausal women experienced symptom relief (Gartrell 
et al., 2001). Other studies reported little evidence for the antidepressant efficacy of estradiol 
in perimenopausal women and recommended an addition of antidepressants to hormonal 
therapies to improve the efficacy (Rubinow, Lanier Johnson, Schmidt, Girdler & Gaynes, 
2015; Studd, 2011).  
However, the small number of included studies, the included studies Schmidt et al., 
(2005) and Soares et al., (2001) have shown contrasting results. The study of Schmidt and 
colleagues (2005) has shown a higher effect size for the placebo group than the treatment 
group, while Soares and colleagues (2001) has shown a higher effect size for the treatment 
group than the placebo group. This could be due the fact that in the study of Schmidt et al., 
(2005) included only women that were placebo-nonresponders. This could have affected the 
study results. Therefore, based on the results of this meta-analysis, it is not possible to 
conclude HRT to be a not efficacious treatment.  
4.2. Limitations 
A critical point of this study is the small number of studies that were eligible for this 
meta-analysis. The reasons for this can be found in strict in- and exclusion criteria and studies 
of authors who did not respond, after they had been contacted by email, were excluded. The 
results of this meta-analysis should be interpreted with great caution and cannot be 
generalized to the population. This meta-analysis is limited by potential publication bias and 
is biased because of including only English-language publications. Studies are reporting not 
standardized outcomes, unclear in- and exclusion criteria and there is a lack of consistency 
between studies. A lack of consistency between studies is most evident in extremely varying 
dose of the medication and/or hormone preparation. Another limitation was that in many 
studies the results were given for perimenopausal and postmenopausal women in one 
outcome. Mixing these results should not be done, because these women are not in the same 
physiologic state (Rubinow et al., 2015).  
This meta-analysis had strict in- and exclusion criteria. One of the important inclusion 
criteria was the definition of menopausal status according to STRAW criteria.  But, one 
exception was made for the study of Ladd (2005); this study was included despite the fact that 
only 7 out of 14 women were recruited according STRAW criteria. If all women would not be 
recruited according STRAW, this would lead to exclusion of this study. However, this 
exception is a limitation , because it could have effected the results.  
  As only one previous study examined the combined treatment effects of ERT and AD 
in perimenopausal women, this meta-analysis did not examine the effectiveness of combined 
treatment. However, many studies support the idea of the effectiveness of a combination of 
estradiol/estrogen and antidepressants. They concluded that estrogen treatments and 
antidepressants therapy are not efficacious monotherapies, a combination is recommended 
(Rubinow, Lanier Johnson, Schmidt, Girdler & Gaynes, 2015; Studd, 2011; Parry, 2010).   
 
 
 
4.3. Recommendations  
This meta-analysis has shown that it is to soon to conclude that the AD treatment is the 
most effective treatment for perimenopausal women who experience depressive symptoms, 
because of some limitations. These limitations, summed up earlier, lead to recommendations 
for future and further research. Studies vary great in design and have contrasting results. 
Differences at recruitment of women, STRAW-criteria, route of administration and dosage of 
medication or hormone preparation causes a lack of consistency between studies. Consistency 
between studies is recommended. Also, larger, standardized, long-term follow-up treatments 
are needed for reliable outcomes. This is needed to accurately determine relative benefits and 
adverse effects of treatments. The challenge for most studies are the recruitment of women, 
which explains the small number of women in the perimenopause state.  
It is recommend for future research to take these limitations in account and create more 
consistency between studies. The effectiveness of the combined treatment of AD and HRT 
should the focus of further research, because many studies support the idea of the 
effectiveness of a combination of estradiol/estrogen and antidepressants.  
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